Angelman syndrome-associated ubiquitin ligase UBE3A/E6AP mutants interfere with the proteolytic activity of the proteasome

Cell Death and Disease

Volumn 6, Issue 1, 2015, Pages

  Tomaic V ^a   Banks, L ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 5A; PROTEASOME; UBIQUITIN LIGASE E6AP; UBIQUITIN LIGASE UBE3A; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; MUTANT PROTEIN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; PROTEIN BINDING; PROTEIN E7; PROTEIN SUBUNIT; UBE3A PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; GENETIC ASSOCIATION; HAPPY PUPPET SYNDROME; HEK293 CELL LINE; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; WILD TYPE; BIOCATALYSIS; ENZYMOLOGY; GENE SILENCING; METABOLISM; PROTEIN DEGRADATION; PROTEIN SUBUNIT; UBIQUITINATION;

ANGELMAN SYNDROME; BIOCATALYSIS; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; MUTANT PROTEINS; PAPILLOMAVIRUS E7 PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN SUBUNITS; PROTEOLYSIS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84927674671     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.572     Document Type: Article

References (47)

1. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009; 458: 438-444.
2. Bernassola F, Karin M, Ciechanover A, Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 2008; 14: 10-21.
3. Edelmann MJ, Nicholson B, Kessler BM. Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Rev Mol Med 2011; 13: e35.
4. Dagli A, Buiting K, Williams CA. Molecular and Clinical Aspects of Angelman Syndrome. Mol Syndromol 2012; 2: 100-112.
5. Williams CA, Driscoll DJ, Dagli AI. Clinical and genetic aspects of Angelman syndrome. Genet Med 2010; 12: 385-395.
6. Huibregtse JM, Scheffner M, Howley PM. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 1993; 13: 775-784.
7. Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001; 20: 7874-7887.
8. Lossie AC, Whitney MM, Amidon D, Dong HJ, Chen P, Theriaque D et al. Distinct phenotypes distinguish the molecular classes of Angelman syndrome. J Med Genet 2001; 38: 834-845.
9. Jiang Y, Lev-Lehman E, Bressler J, Tsai TF, Beaudet AL. Genetics of Angelman syndrome. Am J Hum Genet 1999; 65: 1-6.
10. Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 1997; 15: 70-73.
11. Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, Benton CS et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 1997; 15: 74-77.
12. Malzac P,Webber H, Moncla A, Graham JM, Kukolich M, Williams C et al. Mutation analysis of UBE3A in Angelman syndrome patients. Am J Hum Genet 1998; 62: 1353-1360.
13. Huang L, Kinnucan E,Wang G, Beaudenon S, Howley PM, Huibregtse JM et al. Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science 1999; 286: 1321-1326.
14. Cooper EM, Hudson AW, Amos J, Wagstaff J, Howley PM. Biochemical analysis of Angelman syndrome-associated mutations in the E3 ubiquitin ligase E6-associated protein. J Biol Chem 2004; 279: 41208-41217.
15. Hattori T, Kishino T, Stephen S, Eberspaecher H, Maki S, Takigawa M et al. E6-AP/UBE3A protein acts as a ubiquitin ligase toward SOX9 protein. J Biol Chem 2013; 288: 35138-35148.
16. Pal P, Lochab S, Kanaujiya JK, Kapoor I, Sanyal S, Behre G et al. E6AP, an E3 ubiquitin ligase negatively regulates granulopoiesis by targeting transcription factor C/EBPα for ubiquitin-mediated proteasome degradation. Cell Death Dis 2013; 4: e590.
17. Mulherkar SA, Sharma J, Jana NR. The ubiquitin ligase E6-AP promotes degradation of alpha-synuclein. J Neurochem 2009; 110: 1955-1964.
18. Mishra A, Godavarthi SK, Jana NR. UBE3A/E6-AP regulates cell proliferation by promoting proteasomal degradation of p27. Neurobiol Dis 2009; 36: 26-34.
19. Louria-Hayon I, Alsheich-Bartok O, Levav-Cohen Y, Silberman I, Berger M, Grossman T et al. E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ 2009; 16: 1156-1166.
20. Shimoji T, Murakami K, Sugiyama Y, Matsuda M, Inubushi S, Nasu J et al. Identification of annexin A1 as a novel substrate for E6AP-mediated ubiquitylation. J Cell Biochem 2009; 106: 1123-1135.
21. Mani A, Oh AS, Bowden ET, Lahusen T, Lorick KL, Weissman AM et al. E6AP mediates regulated proteasomal degradation of the nuclear receptor coactivator amplified in breast cancer 1 in immortalized cells. Cancer Res 2006; 66: 8680-8686.
22. Kumar S, Talis AL, Howley PM. Identification of HHR23A as a substrate for E6-associated protein-mediated ubiquitination. J Biol Chem 1999; 274: 18785-18792.
23. Vos RM, Altreuter J, White EA, Howley PM. The ubiquitin-specific peptidase USP15 regulates human papillomavirus type 16 E6 protein stability. J Virol 2009; 83: 8885-8892.
24. Zaaroor-Regev D, de Bie P, Scheffner M, Noy T, Shemer R, Heled M et al. Regulation of the polycomb protein Ring1B by self-ubiquitination or by E6-AP may have implications to the pathogenesis of Angelman syndrome. Proc Natl Acad Sci USA 2010; 107: 6788-6793.
25. Tomaić V, Pim D, Thomas M, Massimi P, Myers MP, Banks L. Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD. J Virol 2011; 85: 3120-3127.
26. Uchiki T, Kim HT, Zhai B, Gygi SP, Johnston JA, O'Bryan JP et al. The ubiquitin-interacting motif protein, S5a, is ubiquitinated by all types of ubiquitin ligases by a mechanism different from typical substrate recognition. J Biol Chem 2009; 284: 12622-12632.
27. Lee SY, Ramirez J, Franco M, Lectez B, Gonzalez M, Barrio R et al. Ube3a, the E3 ubiquitin ligase causing Angelman syndrome and linked to autism, regulates protein homeostasis through the proteasomal shuttle Rpn10. Cell Mol Life Sci 2014; 71: 2747-2758.
28. Kish-Trier E, Hill CP. Structural biology of the proteasome. Annu Rev Biophys 2013; 42: 29-49.
29. Wang Q, Young P, Walters KJ. Structure of S5a bound to monoubiquitin provides a model for polyubiquitin recognition. J Mol Biol 2005; 348: 727-739.
30. Husnjak K, Elsasser S, Zhang N, Chen X, Randles L, Shi Y et al. Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature 2008; 453: 481-488.
31. Isasa M, Katz EJ, Kim W, Yugo V, González S, Kirkpatrick DS et al. Monoubiquitination of RPN10 regulates substrate recruitment to the proteasome. Mol Cell 2010; 38: 733-745.
32. Fu H, Sadis S, Rubin DM, Glickman M, van Nocker S, Finley D et al. Multiubiquitin chain binding and protein degradation are mediated by distinct domains within the 26 S proteasome subunit Mcb1. J Biol Chem 1998; 273: 1970-1981.
33. Elsasser S, Chandler-Militello D, Müller B, Hanna J, Finley D. Rad23 and Rpn10 serve as alternative ubiquitin receptors for the proteasome. J Biol Chem 2004; 279: 26817-26822.
34. Verma R, Oania R, Graumann J, Deshaies RJ. Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin-proteasome system. Cell 2004; 118: 99-110.
35. Kim HT, Kim KP, Uchiki T, Gygi SP, Goldberg AL. S5a promotes protein degradation by blocking synthesis of nondegradable forked ubiquitin chains. EMBO J 2009; 28: 1867-1877.
36. Tomaić V, Ganti K, Pim D, Bauer C, Blattner C, Banks L. Interaction of HPV E6 oncoproteins with specific proteasomal subunits. Virology 2013; 446: 389-396.
37. Martínez-Noël G, Galligan JT, Sowa ME, Arndt V, Overton TM, Harper JW et al. Identification and proteomic analysis of distinct UBE3A/E6AP protein complexes. Mol Cell Biol 2012; 32: 3095-3106.
38. Talis AL, Huibregtse JM, Howley PM. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem 1998; 273: 6439-6445.
39. Morris EJ, Dyson NJ. Retinoblastoma protein partners. Adv Cancer Res 2001; 82: 1-54.
40. Mishra A, Godavarthi SK, Maheshwari M, Goswami A, Jana NR. The ubiquitin ligase E6-AP is induced and recruited to aggresomes in response to proteasome inhibition and may be involved in the ubiquitination of Hsp70-bound misfolded proteins. J Biol Chem 2009; 284: 10537-10545.
41. Wigler M, Sweet R, Sim GK, Wold B, Pellicer A, Lacy E et al. Transformation of mammalian cells with genes from procaryotes and eucaryotes. Cell 1979; 16: 777-785.
42. Tomaić V, Pim D, Banks L. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent. Virology 2009; 393: 7-10.
43. Pim D, Massimi P, Banks L. Alternatively spliced HPV-18 E6∗ protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 1997; 15: 257-264.
44. Gammoh N, Gardiol D, Massimi P, Banks L. The Mdm2 ubiquitin ligase enhances transcriptional activity of human papillomavirus E2. J Virol 2009; 83: 1538-1543.
45. Todorovic B, Hung K, Massimi P, Avvakumov N, Dick FA, Shaw GS et al. Conserved region 3 of human papillomavirus 16 E7 contributes to deregulation of the retinoblastoma tumor suppressor. J Virol 2012; 86: 13313-13323.
46. Jin Y, Zeng SX, Sun XX, Lee H, Blattner C, Xiao Z et al. MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2. Mol Cell Biol 2008; 28: 1218-1229.
47. Thomas M, Laura R, Hepner K, Guccione E, Sawyers C, Lasky L et al. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene 2002; 21: 5088-5096.